Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.905
-0.035 (-1.80%)
Oct 8, 2026, 1:09 PM EDT - Market open
Inhibikase Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 31.21 | 139.22 | 56.49 | 9.17 | 7.19 | 40.75 |
Short-Term Investments | 127.81 | 39.54 | 41.05 | 4.09 | 15.86 | - |
Cash & Short-Term Investments | 159.02 | 178.76 | 97.54 | 13.25 | 23.05 | 40.75 |
Cash Growth | 81.39% | 83.27% | 636.06% | -42.51% | -43.44% | 192.04% |
Receivables | - | - | - | - | 0.04 | 0.11 |
Prepaid Expenses | 0.91 | 0.32 | 0.83 | 0.74 | 0.16 | 1.5 |
Other Current Assets | 2.42 | 1.03 | 0.08 | 0.22 | 1.12 | 0.11 |
Total Current Assets | 162.34 | 180.11 | 98.45 | 14.21 | 24.37 | 42.47 |
Property, Plant & Equipment | - | - | 0.15 | 0.3 | 0.57 | - |
Other Long-Term Assets | 1.24 | 1.1 | - | - | - | - |
Total Assets | 163.59 | 181.2 | 98.6 | 14.51 | 24.94 | 42.47 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.99 | 1.16 | 0.94 | 0.65 | 1.15 | 1.09 |
Accrued Expenses | 9.27 | 4.08 | 2.68 | 2.26 | 2.4 | 2.72 |
Short-Term Debt | - | - | - | 0.38 | - | - |
Current Portion of Long-Term Debt | - | - | - | - | - | 0.25 |
Current Portion of Leases | - | - | 0.11 | 0.15 | 0.15 | - |
Other Current Liabilities | - | 3.06 | - | - | - | - |
Total Current Liabilities | 10.26 | 8.3 | 3.73 | 3.44 | 3.7 | 4.05 |
Long-Term Leases | - | - | - | 0.09 | 0.21 | - |
Total Liabilities | 10.26 | 8.3 | 3.73 | 3.53 | 3.9 | 4.05 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.13 | 0.13 | 0.07 | 0.01 | 0 | 0.03 |
Additional Paid-In Capital | 331.92 | 315.43 | 189.25 | 77.87 | 68.8 | 68.21 |
Retained Earnings | -178.65 | -142.68 | -94.42 | -66.9 | -47.87 | -29.82 |
Comprehensive Income & Other | -0.07 | 0.02 | -0.04 | 0 | 0.1 | - |
Shareholders' Equity | 153.33 | 172.9 | 94.87 | 10.98 | 21.04 | 38.42 |
Total Liabilities & Equity | 163.59 | 181.2 | 98.6 | 14.51 | 24.94 | 42.47 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | 0.11 | 0.62 | 0.35 | 0.25 |
Net Cash (Debt) | 159.02 | 178.76 | 97.43 | 12.63 | 22.7 | 40.5 |
Net Cash Growth | 81.47% | 83.47% | 671.44% | -44.36% | -43.95% | 197.05% |
Net Cash Per Share | 1.13 | 1.82 | 4.11 | 2.10 | 5.37 | 13.35 |
Filing Date Shares Outstanding | 182.07 | 170.42 | 90.01 | 6.48 | 4.83 | 4.2 |
Total Common Shares Outstanding | 174.57 | 170.08 | 89.18 | 6.19 | 4.2 | 4.19 |
Working Capital | 152.08 | 171.81 | 94.72 | 10.77 | 20.68 | 38.42 |
Book Value Per Share | 0.88 | 1.02 | 1.06 | 1.77 | 5.00 | 9.16 |
Tangible Book Value | 153.33 | 172.9 | 94.87 | 10.98 | 21.04 | 38.42 |
Tangible Book Value Per Share | 0.88 | 1.02 | 1.06 | 1.77 | 5.00 | 9.16 |
Machinery | - | - | 0.1 | 0.1 | 0.24 | - |